Clinical Trial

A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer

Study acronym: CLEAR-04
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Patients with T4N+ or T1-3N2 disease will be randomly assigned to either the control group (FOLFOX/CAPOX for 6 months) or the intervention group (FOLFOX/CAPOX plus bevacizumab for 6 months) to receive adjuvant therapy. Venous blood samples (8-16 mL) will be collected at 1 month, 3 months, and 6 months postoperatively for dynamic monitoring of plasma ctDNA.
Trial Details
NCT Number NCT07562490
Lead Sponsor Fudan University
Conditions ctDNA, Chemotherapy, Colorectal Cancer
Enrollment 100 participants
Start Date 2025-04-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-01